Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Alchemab Therapeutics has raised $33.6M in total funding. The most recent round was Series A. The last funding was announced in July 2026.
Alchemab Therapeutics's investors include RA Capital Management, British Business Bank, Eli Lilly, SV Health Investors, DCVC Bio.
Alchemab Therapeutics is headquartered in London, United Kingdom.
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Alchemab Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alchemab Therapeutics — Funding & Investors." VCBacked, July 9, 2026, https://www.vcbacked.co/company/alchemab-therapeutics. Accessed September 3, 2026.
VCBacked. (2026). Alchemab Therapeutics — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/alchemab-therapeutics
{{cite web |title=Alchemab Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alchemab-therapeutics |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated